Median progression-free survival was significantly longer in the trebananib group than in the placebo group ( 72 months [ 58-74 ] vs 54 months [ 95 % CI 43-55 ] , respectively , hazard ratio 066 , 95 % CI 057-077 , p < 00001 ) .